Loading
A phase 2 trial of mitazalimab in pancreatic cancer, run by University of Pennsylvania, now recruiting.
Maintenance Combinatorial Myeloid Immunotherapy for Unresectable Pancreatic Cancer is a phase 2, interventional study registered as NCT07199764 by University of Pennsylvania, with a registry enrolment figure of 100 participants, started 2025-11-25 and due to reach its primary completion in 2027-10. Interventions recorded: Odetiglucan; Mitazalimab. Conditions listed: Pancreatic Ductal Adenocarcinoma. Primary outcome: Median progression-free survival (mPFS) of 7.5 months in Cohort A. Pancreatic eligibility wording from the registry: "* Histologically or cytologically confirmed diagnosis of pancreatic adenocarcinoma that is either locally advanced and unresectable, or metastatic". Sites: United States. No results are recorded here; the registry entry is the source.
Shares Locally advanced unresectable pancreatic ductal adenocarcinoma, Pancreatic cancer trials open today (registry snapshot and UK sites), Metastatic pancreatic ductal adenocarcinoma and the tag pancreatic-deep-dive.
Shares Locally advanced unresectable pancreatic ductal adenocarcinoma, Pancreatic cancer trials open today (registry snapshot and UK sites), Metastatic pancreatic ductal adenocarcinoma and the tag pancreatic-deep-dive.
Shares Locally advanced unresectable pancreatic ductal adenocarcinoma, Pancreatic cancer trials open today (registry snapshot and UK sites), Metastatic pancreatic ductal adenocarcinoma and the tag pancreatic-deep-dive.
Shares Locally advanced unresectable pancreatic ductal adenocarcinoma, Pancreatic cancer trials open today (registry snapshot and UK sites), Metastatic pancreatic ductal adenocarcinoma and the tag pancreatic-deep-dive.
Shares Locally advanced unresectable pancreatic ductal adenocarcinoma, Pancreatic cancer trials open today (registry snapshot and UK sites), Metastatic pancreatic ductal adenocarcinoma and the tag pancreatic-deep-dive.
Shares Locally advanced unresectable pancreatic ductal adenocarcinoma, Pancreatic cancer trials open today (registry snapshot and UK sites), Metastatic pancreatic ductal adenocarcinoma and the tag pancreatic-deep-dive.
Shares Locally advanced unresectable pancreatic ductal adenocarcinoma, Pancreatic cancer trials open today (registry snapshot and UK sites), Metastatic pancreatic ductal adenocarcinoma and the tag pancreatic-deep-dive.
Shares Locally advanced unresectable pancreatic ductal adenocarcinoma, Pancreatic cancer trials open today (registry snapshot and UK sites), Metastatic pancreatic ductal adenocarcinoma and the tag pancreatic-deep-dive.